CN112370429A - Direct-compression type organic calcium vitamin D3 chewable tablet and preparation method thereof - Google Patents
Direct-compression type organic calcium vitamin D3 chewable tablet and preparation method thereof Download PDFInfo
- Publication number
- CN112370429A CN112370429A CN201911001903.0A CN201911001903A CN112370429A CN 112370429 A CN112370429 A CN 112370429A CN 201911001903 A CN201911001903 A CN 201911001903A CN 112370429 A CN112370429 A CN 112370429A
- Authority
- CN
- China
- Prior art keywords
- calcium
- parts
- vitamin
- chewable tablet
- organic calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000011575 calcium Substances 0.000 title claims abstract description 130
- 229910052791 calcium Inorganic materials 0.000 title claims abstract description 130
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract description 128
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 title claims abstract description 113
- 239000011647 vitamin D3 Substances 0.000 title claims abstract description 92
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 title claims abstract description 92
- 235000005282 vitamin D3 Nutrition 0.000 title claims abstract description 92
- 229940021056 vitamin d3 Drugs 0.000 title claims abstract description 92
- 239000007910 chewable tablet Substances 0.000 title claims abstract description 68
- 229940068682 chewable tablet Drugs 0.000 title claims abstract description 57
- 238000007907 direct compression Methods 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title abstract description 19
- 229960005069 calcium Drugs 0.000 claims abstract description 129
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 76
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 62
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims abstract description 54
- 235000010355 mannitol Nutrition 0.000 claims abstract description 42
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims abstract description 33
- 239000001354 calcium citrate Substances 0.000 claims abstract description 33
- 235000013337 tricalcium citrate Nutrition 0.000 claims abstract description 33
- 239000004376 Sucralose Substances 0.000 claims abstract description 32
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims abstract description 32
- 235000019408 sucralose Nutrition 0.000 claims abstract description 32
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 31
- MKJXYGKVIBWPFZ-CEOVSRFSSA-L calcium;(2s)-2-hydroxypropanoate Chemical compound [Ca+2].C[C@H](O)C([O-])=O.C[C@H](O)C([O-])=O MKJXYGKVIBWPFZ-CEOVSRFSSA-L 0.000 claims abstract description 31
- 229960001031 glucose Drugs 0.000 claims abstract description 31
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 31
- 238000010521 absorption reaction Methods 0.000 claims abstract description 28
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 27
- 229920001100 Polydextrose Polymers 0.000 claims abstract description 27
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 27
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 27
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 27
- 239000001259 polydextrose Substances 0.000 claims abstract description 27
- 229940035035 polydextrose Drugs 0.000 claims abstract description 27
- 235000013856 polydextrose Nutrition 0.000 claims abstract description 27
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 9
- 239000003623 enhancer Substances 0.000 claims abstract description 8
- 229930003316 Vitamin D Natural products 0.000 claims description 21
- 235000019166 vitamin D Nutrition 0.000 claims description 21
- 239000011710 vitamin D Substances 0.000 claims description 21
- 229940046008 vitamin d Drugs 0.000 claims description 21
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 19
- 239000000463 material Substances 0.000 claims description 16
- 239000002202 Polyethylene glycol Substances 0.000 claims description 15
- 229920001223 polyethylene glycol Polymers 0.000 claims description 15
- 239000011230 binding agent Substances 0.000 claims description 12
- 230000001678 irradiating effect Effects 0.000 claims description 9
- 238000007789 sealing Methods 0.000 claims description 9
- 229930195725 Mannitol Natural products 0.000 claims description 8
- 239000000594 mannitol Substances 0.000 claims description 8
- 238000007873 sieving Methods 0.000 claims description 8
- 238000005303 weighing Methods 0.000 claims description 8
- 229940124532 absorption promoter Drugs 0.000 claims description 5
- 208000007442 rickets Diseases 0.000 abstract description 7
- 239000003826 tablet Substances 0.000 abstract description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 6
- 230000007794 irritation Effects 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 208000005368 osteomalacia Diseases 0.000 abstract description 3
- 229940088594 vitamin Drugs 0.000 abstract 3
- 229930003231 vitamin Natural products 0.000 abstract 3
- 235000013343 vitamin Nutrition 0.000 abstract 3
- 239000011782 vitamin Substances 0.000 abstract 3
- 150000003722 vitamin derivatives Chemical class 0.000 abstract 3
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 19
- 206010006956 Calcium deficiency Diseases 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 11
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 8
- 241000700159 Rattus Species 0.000 description 6
- 210000003754 fetus Anatomy 0.000 description 6
- 150000004686 pentahydrates Chemical class 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 206010003210 Arteriosclerosis Diseases 0.000 description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- -1 absorption promoter Chemical compound 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 2
- 229940069978 calcium supplement Drugs 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 206010005963 Bone formation increased Diseases 0.000 description 1
- 206010006322 Breath holding Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 241001456553 Chanodichthys dabryi Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 206010070538 Gestational hypertension Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 201000005624 HELLP Syndrome Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 208000034702 Multiple pregnancies Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 101100273664 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) ccp-1 gene Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 206010034203 Pectus Carinatum Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 208000005347 Pregnancy-Induced Hypertension Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000035563 calcemia Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000003913 calcium metabolism Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 208000002296 eclampsia Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 208000018944 leg cramp Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000007180 physiological regulation Effects 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 208000036335 preeclampsia/eclampsia 1 Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 206010039722 scoliosis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 230000003813 thin hair Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the technical field of health-care product production, and particularly relates to a direct-compression organic calcium vitamin D3 chewable tablet and a preparation method thereof. The vitamin tablet mainly comprises vitamin D3, calcium citrate, L-calcium lactate, D-mannitol, microcrystalline cellulose, anhydrous glucose, polyethylene glycol 6000, sucralose, magnesium stearate and an absorption enhancer. The calcium-containing vitamin tablet disclosed by the invention uses organic acid calcium, has small irritation to gastrointestinal tracts and higher solubility and absorptivity; the vitamin D3 is used in combination with polydextrose, calcium citrate and L-calcium lactate, and is beneficial for absorption and utilization of calcium, and the vitamin D3 can prevent rickets in infants and osteomalacia in adults; the invention adopts a direct compression method to produce the vitamin tablets, and the preparation method is simple.
Description
Technical Field
The invention belongs to the technical field of health-care product production, and particularly relates to a direct-compression organic calcium vitamin D3 chewable tablet and a preparation method thereof.
Background
Calcium is the most abundant mineral element in human body, and accounts for 1.5% -2.0% of the body weight, and the total weight reaches 1200-1300g, wherein 99% of calcium exists in bones and teeth to form a human body scaffold and serve as a calcium reservoir of the body; the rest are distributed in blood, extracellular fluid and soft tissue cells, collectively called the miscible calcium pool, and maintain dynamic balance with bone calcium. Basically, all life processes of the organism require the participation of calcium, and the balance of calcium metabolism is an important factor for maintaining life and health. Calcium plays an extremely important role in physiological regulation in physiological processes such as nerve and muscle stress, nerve impulse conduction, heart rhythm maintenance, blood coagulation, cell adhesion and the like, and a plurality of diseases can be caused by calcium deficiency of a human body.
1) Calcium deficiency of pregnant women: when the fetus grows to a term infant from a fertilized egg, a large amount of nutrient substances need to be taken from the mother, calcium is taken from the mother every moment in the development process of the fetus so as to meet the growth and development requirements of the fetus, and when the mother is in a calcium deficiency state, the calcium required by the fetus only can use the calcium in the bone of the mother, so that the osteoporosis of the pregnant woman is caused. The early symptom of calcium deficiency in pregnant women is leg cramps. The lack of calcium in pregnant women can also cause pregnancy-induced hypertension syndrome, three main symptoms of edema, hypertension and proteinuria, and serious lack of calcium can cause eclampsia and endanger life.
The calcium deficiency of multiparous women is more serious, the osteoporosis becomes more and more serious after multiple pregnancies, besides the symptoms of lumbocrural pain, dwarfing, hunchback, easy fracture and the like, the pelvis of the multiparous women is deformed due to osteomalacia, and the fetus cannot be normally delivered, but can be delivered by a caesarean delivery mode. The common symptoms of puerperal hypodynamia, dizziness, body pain, even difficult turnover and the like are the manifestations of calcium deficiency. When the mother is seriously deficient in calcium, the fetus may suffer from congenital rickets after birth.
2) Calcium deficiency of children and teenagers: the calcium deficiency of children is manifested by thin hair, yellow hair, alopecia occipitalis, night convulsion, late teeth, late learning to walk, and weakness and sickliness. Susceptible to tetany, common cold, tracheitis, eczema, myopia, dental caries, osteodynia, enterospasm, abdominal pain, and hyperkinetic syndrome; rickets can be caused by serious calcium deficiency. Rickets caused by calcium deficiency of children, such as rachitis bone deformation, beading, chicken breast, humpback, scoliosis, X-shaped leg and O-shaped leg, may remain for a lifetime. Calcium deficiency in adolescent male and female can lead to poor bone growth, listlessness, energy deficiency, leg cramp, bone deformation left by rickets in children, mental disorder, inferior, autism and even adolescent psychosis.
3) Calcium deficiency in the elderly: the middle-aged and the elderly are easy to suffer from osteoporosis, hyperosteogeny, scapulohumeral periarthritis and other diseases due to calcium deficiency. Calcium deficiency induced tissue sclerosis can lead to calculus, arteriosclerosis, etc. The symptoms presented differ from one arteriosclerosis to another: systemic vascular arteriosclerosis can lead to hypertension; cerebral arteriosclerosis, which may cause epilepsy, Parkinson's syndrome and even senile dementia; pancreatic arteriosclerosis is not beneficial to the secretion of insulin, so that blood sugar is increased, and diabetes is induced; coronary arteriosclerosis, which nourishes myocardium, can cause myocardial ischemia, coronary heart disease, paroxysmal pain, chest distress and breath holding in precordial region, and death due to myocardial infarction and cardiogenic shock in severe cases.
Because the grain and vegetable are taken as staple food in China, the phytic acid, oxalic acid and tannic acid in the grain and vegetable can inhibit calcium absorption; in addition, the cooking mode of daily food, irregular life of modern people and the three-high eating habits of high protein, high fat and high carbohydrate lead to the general shortage of the calcium intake of human bodies. Chinese nutrition survey shows that the intake of national calcium is generally low, about 400-500mg each day, and only reaches about 50% of recommended amount. Calcium should be reasonably supplemented to maintain health, especially for infants, children, the elderly, pregnant women, lactating women and climacteric women. Therefore, the calcium supplement health care product becomes one of the health care products with huge consumption.
The patent publication No. 20101003243.8 discloses a method for preparing vitamin D calcium soft capsules, which comprises calcium carbonate powder, vitamin D3, soybean salad oil, soybean lecithin, beeswax and other raw materials, and the prepared vitamin D calcium soft capsules can increase the absorption of calcium and vitamin D in human body. However, the vitamin D calcium soft capsule has a stimulating effect on the stomach and can influence the absorption of other substances.
At present, calcium supplement health care products in the market have the problems of low solubility and absorptivity, unreasonable daily intake design, general product orientation to people and the like.
Disclosure of Invention
In order to overcome the defects in the prior art, the invention aims to provide a direct-compression organic calcium vitamin D3 chewable tablet and a preparation method thereof. The vitamin D3 chewable tablet provided by the invention has small irritation to intestinal tracts and higher solubility and absorptivity, and is beneficial to absorption and utilization of calcium.
In order to achieve the purpose, the technical scheme of the invention is as follows:
a direct-compression organic calcium vitamin D3 chewable tablet mainly comprises the following components in parts by weight: 90-130 parts of organic calcium, 25-45 parts of binder, 1-10 parts of anhydrous glucose, 10-30 parts of D-mannitol, 60001-10 parts of polyethylene glycol, 35-25 parts of vitamin D, 0.5-1.5 parts of absorption enhancer, 1-9 parts of sucralose and 0.5-2 parts of magnesium stearate.
Further, the direct compression type organic calcium vitamin D3 chewable tablet comprises the following components in parts by weight: 114 parts of organic calcium, 34 parts of binder, 5 parts of anhydrous glucose, 23.38 parts of D-mannitol, 60004 parts of polyethylene glycol, 312 parts of vitamin D, 1 part of absorption enhancer, 5 parts of sucralose and 1.62 parts of magnesium stearate.
Furthermore, the organic calcium consists of L-calcium lactate and calcium citrate according to the weight ratio of 4-6: 5-7.
Furthermore, the organic calcium consists of L-calcium lactate and calcium citrate according to the weight ratio of 5: 6.4.
Further, the binder is microcrystalline cellulose, and the absorption promoter is polydextrose.
The invention also provides a preparation method of the direct pressure type organic calcium vitamin D3 chewable tablet, which comprises the following steps:
s1, removing the outer package of organic calcium, binder, anhydrous glucose, D-mannitol, polyethylene glycol 6000, vitamin D3, absorption promoter, sucralose and magnesium stearate, and irradiating for 30 minutes under an ultraviolet lamp;
s2, sieving the D-mannitol with a 20-mesh sieve, and weighing the components according to the formula;
s3, adding sucralose, vitamin D3 and an absorption promoter into a three-dimensional mixer, mixing at the motor frequency of 25-30Hz for 5 minutes, adding organic calcium, a binder, anhydrous glucose, D mannitol, polyethylene glycol 6000 and magnesium stearate, and continuously mixing for 15 minutes;
s4, tabletting the uniformly mixed materials, bottling and sealing to obtain the finished product.
The calcium citrate and the L-calcium lactate are used for providing calcium, and both are organic calcium, so that the calcium citrate and the L-calcium lactate are more favorable for digestion and absorption than inorganic calcium, have small irritation to intestinal tracts, and are favorable for children, old people, pregnant women and other people to eat.
As the calcium citrate is in a fine powder shape, the problems of excessive whole fine powder of the material, poor material flowability, low cohesive force, substandard hardness and friability and the like are caused. The addition of the L-calcium lactate not only provides a plurality of organic calcium substances, but also improves the material fluidity and reduces the fine powder amount; the compressibility of the material can be improved by adopting the D-mannitol, the good compressibility also increases the binding power among the materials, the hardness of the chewable tablet is improved together with the microcrystalline cellulose serving as a binding agent, and meanwhile, the D-mannitol has no granular feeling, can absorb heat when dissolved in the mouth and generates cool feeling; the use of a small amount of polyethylene glycol 6000 can improve the hardness and friability of the chewable tablet, and can also improve the surface brightness of the chewable tablet and improve the appearance and the feeling of the chewable tablet. The use of the main raw materials and auxiliary materials can ensure that the hardness and friability of the chewable tablets are qualified, and meanwhile, the chewable tablets cannot mechanically damage a machine, so that the expanded production is facilitated. The water-soluble dietary fiber polydextrose can further promote the absorption of calcium.
Compared with the prior art, the direct-compression organic calcium vitamin D3 chewable tablet provided by the invention has the following advantages:
(1) at present, the calcium vitamin D health food is mainly applied to inorganic calcium carbonate mostly. Mainly because the inorganic calcium has high calcium content, low cost and simple and mature process, the absorption of the inorganic calcium needs gastric acid, the solubility and the absorption rate of the inorganic calcium are lower for people with weak or bad gastrointestinal tracts (such as children, old people, pregnant women and the like), and the stimulation effect on the gastrointestinal tracts is increased, so that the digestion and the absorption of other nutrient substances are influenced. The product uses organic calcium citrate and L-calcium lactate, the absorption of the organic calcium is not greatly related to the level of gastric acid, the irritation to gastrointestinal tract is small, the dissolubility and the absorption rate are higher, and the bioavailability of the calcium is improved.
(2) Vitamin D3 can be used in combination with polydextrose, calcium citrate and L-calcium lactate to facilitate absorption and utilization of calcium, and vitamin D3 can be used for preventing infantile rickets and osteomalacia of adults.
(3) Most of competitive product processes of the calcium vitamin D chewable tablets are granulation and tabletting, and the direct compression method production can be realized by adopting D-mannitol to assist microcrystalline cellulose through the combined use of organic calcium with different properties in the item.
(4) The direct-compression type calcium and vitamin D3 chewable tablet disclosed by the invention is a calcium and vitamin D chewable tablet which is easy to absorb and utilize, scientific in formula design and suitable for pregnant women and lactating women.
Drawings
Fig. 1 is a flow chart of the preparation process of the direct compression type organic calcium vitamin D3 chewable tablet.
Detailed Description
The present invention will be further described below by way of specific embodiments, but the present invention is not limited to only the following examples. Various modifications may be made by those skilled in the art based on the basic idea of the invention, but it is within the scope of the invention as long as it does not depart from the basic idea of the invention.
The preparation process of the chewing tablet of the embodiment, in which the straight-pressure type organic calcium vitamin D3 is shown in fig. 1, wherein, CCP 1: the pre-mixing time of the sucralose, the vitamin D3 and the absorption promoter is 5 minutes; the total mixing time of all materials is 20 minutes; CCP 2: sheet hardness: 230-250N; CCP 3: the bottled sealing performance is qualified; the gray stripe process is a waste dot.
Example 1A direct compression type chewable tablet containing organic calcium and vitamin D3
The direct pressure type organic calcium vitamin D3 chewable tablet comprises the following components in parts by weight: 50 parts of calcium citrate, 40 parts of L-calcium lactate, 25 parts of microcrystalline cellulose, 1 part of anhydrous glucose, 10 parts of D-mannitol, 60001 parts of polyethylene glycol, 35 parts of vitamin D, 0.5 part of polydextrose, 1 part of sucralose and 0.5 part of magnesium stearate.
As shown in fig. 1, the preparation method of the direct compression type organic calcium vitamin D3 chewable tablet comprises the following steps:
s1, removing outer packages of calcium citrate, L-calcium lactate, microcrystalline cellulose, anhydrous glucose, D-mannitol, polyethylene glycol 6000, vitamin D3, polydextrose, sucralose and magnesium stearate, and irradiating for 30 minutes under an ultraviolet lamp;
s2, sieving the D-mannitol with a 20-mesh sieve, and weighing the components according to the formula;
s3, adding sucralose, vitamin D3 and polydextrose into a three-dimensional mixer, mixing at the motor frequency of 25Hz for 5 minutes, adding calcium citrate, L-calcium lactate (pentahydrate), microcrystalline cellulose, anhydrous glucose, D mannitol, polyethylene glycol 6000 and magnesium stearate, and continuously mixing for 15 minutes;
s4, tabletting the uniformly mixed materials, bottling and sealing to obtain the finished product.
Example 2A direct compression type chewable tablet containing organic calcium and vitamin D3
The direct pressure type organic calcium vitamin D3 chewable tablet comprises the following components in parts by weight: 55 parts of calcium citrate, 45 parts of L-calcium lactate, 30 parts of microcrystalline cellulose, 3 parts of anhydrous glucose, 15 parts of D-mannitol, 60003 parts of polyethylene glycol, 310 parts of vitamin D, 0.7 part of polydextrose, 3 parts of sucralose and 0.9 part of magnesium stearate.
As shown in fig. 1, the preparation method of the direct compression type organic calcium vitamin D3 chewable tablet comprises the following steps:
s1, removing outer packages of calcium citrate, L-calcium lactate, microcrystalline cellulose, anhydrous glucose, D-mannitol, polyethylene glycol 6000, vitamin D3, polydextrose, sucralose and magnesium stearate, and irradiating for 30 minutes under an ultraviolet lamp;
s2, sieving the D-mannitol with a 20-mesh sieve, and weighing the components according to the formula;
s3, adding sucralose, vitamin D3 and polydextrose into a three-dimensional mixer, mixing at the motor frequency of 27Hz for 5 minutes, adding calcium citrate, L-calcium lactate (pentahydrate), microcrystalline cellulose, anhydrous glucose, D mannitol, polyethylene glycol 6000 and magnesium stearate, and continuously mixing for 15 minutes;
s4, tabletting the uniformly mixed materials, bottling and sealing to obtain the finished product.
Example 3A direct compression type chewable tablet containing organic calcium and vitamin D3
The direct pressure type organic calcium vitamin D3 chewable tablet comprises the following components in parts by weight: 60 parts of calcium citrate, 50 parts of L-calcium lactate, 35 parts of microcrystalline cellulose, 5 parts of anhydrous glucose, 20 parts of D-mannitol, 60005 parts of polyethylene glycol, 315 parts of vitamin D, 0.9 part of polydextrose, 5 parts of sucralose and 1.3 parts of magnesium stearate.
As shown in fig. 1, the preparation method of the direct compression type organic calcium vitamin D3 chewable tablet comprises the following steps:
s1, removing outer packages of calcium citrate, L-calcium lactate, microcrystalline cellulose, anhydrous glucose, D-mannitol, polyethylene glycol 6000, vitamin D3, polydextrose, sucralose and magnesium stearate, and irradiating under an ultraviolet lamp for 30 minutes;
s2, sieving the D-mannitol with a 20-mesh sieve, and weighing the components according to the formula;
s3, adding sucralose, vitamin D3 and polydextrose into a three-dimensional mixer, mixing at the motor frequency of 28Hz for 5 minutes, adding calcium citrate, L-calcium lactate (pentahydrate), microcrystalline cellulose, anhydrous glucose, D mannitol, polyethylene glycol 6000 and magnesium stearate, and continuously mixing for 15 minutes;
s4, tabletting the uniformly mixed materials, bottling and sealing to obtain the finished product.
Example 4A direct compression type chewable tablet containing organic calcium and vitamin D3
The direct pressure type organic calcium vitamin D3 chewable tablet comprises the following components in parts by weight: 65 parts of calcium citrate, 55 parts of L-calcium lactate, 40 parts of microcrystalline cellulose, 7 parts of anhydrous glucose, 25 parts of D-mannitol, 60007 parts of polyethylene glycol, 320 parts of vitamin D, 1 part of polydextrose, 7 parts of sucralose and 1.7 parts of magnesium stearate.
As shown in fig. 1, the preparation method of the direct compression type organic calcium vitamin D3 chewable tablet comprises the following steps:
s1, removing outer packages of calcium citrate, L-calcium lactate, microcrystalline cellulose, anhydrous glucose, D-mannitol, polyethylene glycol 6000, vitamin D3, polydextrose, sucralose and magnesium stearate, and irradiating for 30 minutes under an ultraviolet lamp;
s2, sieving the D-mannitol with a 20-mesh sieve, and weighing the components according to the formula;
s3, adding sucralose, vitamin D3 and polydextrose into a three-dimensional mixer, mixing at the motor frequency of 29Hz for 5 minutes, adding calcium citrate, L-calcium lactate (pentahydrate), microcrystalline cellulose, anhydrous glucose, D mannitol, polyethylene glycol 6000 and magnesium stearate, and continuously mixing for 15 minutes;
s4, tabletting the uniformly mixed materials, bottling and sealing to obtain the finished product.
Example 5A direct compression type chewable tablet containing organic calcium and vitamin D3
The direct pressure type organic calcium vitamin D3 chewable tablet comprises the following components in parts by weight: 70 parts of calcium citrate, 60 parts of L-calcium lactate, 45 parts of microcrystalline cellulose, 10 parts of anhydrous glucose, 30 parts of D-mannitol, 600010 parts of polyethylene glycol, 325 parts of vitamin D, 1.5 parts of polydextrose, 9 parts of sucralose and 2 parts of magnesium stearate.
As shown in fig. 1, the preparation method of the direct compression type organic calcium vitamin D3 chewable tablet comprises the following steps:
s1, removing outer packages of calcium citrate, L-calcium lactate, microcrystalline cellulose, anhydrous glucose, D-mannitol, polyethylene glycol 6000, vitamin D3, polydextrose, sucralose and magnesium stearate, and irradiating for 30 minutes under an ultraviolet lamp;
s2, sieving the D-mannitol with a 20-mesh sieve, and weighing the components according to the formula;
s3, adding sucralose, vitamin D3 and polydextrose into a three-dimensional mixer, mixing at the motor frequency of 30Hz for 5 minutes, adding calcium citrate, L-calcium lactate (pentahydrate), microcrystalline cellulose, anhydrous glucose, D mannitol, polyethylene glycol 6000 and magnesium stearate, and continuously mixing for 15 minutes;
s4, tabletting the uniformly mixed materials, bottling and sealing to obtain the finished product.
Example 6A direct compression type chewable tablet containing organic calcium and vitamin D3
The direct pressure type organic calcium vitamin D3 chewable tablet comprises the following components in parts by weight: 64 parts of calcium citrate, 50 parts of L-calcium lactate, 34 parts of microcrystalline cellulose, 5 parts of anhydrous glucose, 23.38 parts of D-mannitol, 60004 parts of polyethylene glycol, 312 parts of vitamin D, 1 part of polydextrose, 5 parts of sucralose and 1.62 parts of magnesium stearate.
As shown in fig. 1, the preparation method of the direct compression type organic calcium vitamin D3 chewable tablet comprises the following steps:
s1, removing outer packages of calcium citrate, L-calcium lactate, microcrystalline cellulose, anhydrous glucose, D-mannitol, polyethylene glycol 6000, vitamin D3, polydextrose, sucralose and magnesium stearate, and irradiating for 30 minutes under an ultraviolet lamp;
s2, sieving the D-mannitol with a 20-mesh sieve, and weighing the components according to the formula;
s3, adding sucralose, vitamin D3 and polydextrose into a three-dimensional mixer, mixing at the motor frequency of 30Hz for 5 minutes, adding calcium citrate, L-calcium lactate (pentahydrate), microcrystalline cellulose, anhydrous glucose, D mannitol, polyethylene glycol 6000 and magnesium stearate, and continuously mixing for 15 minutes;
s4, tabletting the uniformly mixed materials, bottling and sealing to obtain the finished product.
Comparative example 1, a direct compression type organic calcium vitamin D3 chewable tablet
The direct pressure type organic calcium vitamin D3 chewable tablet comprises the following components in parts by weight: 114 parts of calcium citrate, 34 parts of microcrystalline cellulose, 5 parts of anhydrous glucose, 23.38 parts of D-mannitol, 60004 parts of polyethylene glycol, 312 parts of vitamin D, 1 part of polydextrose, 5 parts of sucralose and 1.62 parts of magnesium stearate.
The preparation method of the direct pressure type organic calcium vitamin D3 chewable tablet is similar to example 6.
The difference from example 6 is that the organic calcium is entirely calcium citrate.
Comparative example 2, a direct compression type organic calcium vitamin D3 chewable tablet
The direct pressure type organic calcium vitamin D3 chewable tablet comprises the following components in parts by weight: 64 parts of calcium citrate, 50 parts of L-calcium lactate, 5 parts of anhydrous glucose, 23.38 parts of D-mannitol, 60004 parts of polyethylene glycol, 312 parts of vitamin D, 1 part of polydextrose, 5 parts of sucralose and 1.62 parts of magnesium stearate.
The preparation method of the direct pressure type organic calcium vitamin D3 chewable tablet is similar to example 6.
The difference from example 6 is that microcrystalline cellulose was not added as a binder.
Comparative example 3, a direct compression type organic calcium vitamin D3 chewable tablet
The direct pressure type organic calcium vitamin D3 chewable tablet comprises the following components in parts by weight: 64 parts of calcium citrate, 50 parts of L-calcium lactate, 34 parts of microcrystalline cellulose, 5 parts of anhydrous glucose, 23.38 parts of D-mannitol, 60004 parts of polyethylene glycol, 312 parts of vitamin D, 5 parts of sucralose and 1.62 parts of magnesium stearate.
The preparation method of the direct pressure type organic calcium vitamin D3 chewable tablet is similar to example 6.
The difference from example 6 is that no absorption enhancer polydextrose is added.
Comparative example 4A direct compression calcium-added vitamin D3 chewable tablet
The direct pressure type organic calcium vitamin D3 chewable tablet comprises the following components in parts by weight: 114 parts of calcium carbonate, 34 parts of microcrystalline cellulose, 5 parts of anhydrous glucose, 23.38 parts of D-mannitol, 60004 parts of polyethylene glycol, 312 parts of vitamin D, 1 part of polydextrose, 5 parts of sucralose and 1.62 parts of magnesium stearate.
The preparation method of the direct pressure type organic calcium vitamin D3 chewable tablet is similar to example 6.
The difference from example 6 is that the organic calcium material is entirely replaced by inorganic calcium carbonate.
Test example 1 calcium absorption Rate measurement experiment
Test samples: calcium-containing vitamin D3 chewable tablets prepared in examples 1-6 and comparative examples 1-4.
Test animals: 200 weaned SD rats born 21 days are half male and female, and have good health condition.
The test method comprises the following steps: after 4 days of adaptive feeding, the SD rats were randomly divided into 10 groups of 20 animals each. The animals were named as example 1 group-example 6 group, comparative example 1 group-comparative example 4 group, and SD rats were fed with a low calcium feed plus the calcium and vitamin D3 tablet prepared in the corresponding example, and the prepared calcium and vitamin D3 tablet was crushed and incorporated into the low calcium feed for feeding.
Calcium ions in the blood of SD rats were measured 0.5 hours after feeding (20 SD rats per group were randomly divided into 10 groups, 0.3ml of submandibular venous blood was collected after SD rats were anesthetized, blood was collected once for half an hour for 5 hours for one cycle), and the amount of increase in blood calcium (%) (blood calcium concentration-raw blood calcium concentration)/raw blood calcium concentration × 100% was calculated, and the time a when the increase in blood calcium started to exceed 2%, the maximum blood calcium increase B, the time B, and the time C when the increase in blood calcium was again lower than 2% (blood collection was stopped) were recorded, as shown in table 1.
TABLE 1 Calcemia parameters
Group of | Time A/h | Time B/h | Increase B/%) | Time C/h |
Example 1 | 1.5 | 2.6 | 5.7 | 5.5 |
Example 2 | 1.5 | 2.5 | 5.5 | 5.5 |
Example 3 | 1.6 | 2.5 | 5.7 | 5.6 |
Example 4 | 1.5 | 2.7 | 5.4 | 5.4 |
Example 5 | 1.4 | 2.5 | 5.5 | 5.4 |
Example 6 | 1.3 | 2.4 | 6.0 | 6.1 |
Comparative example 1 | 2.3 | 3.8 | 3.5 | 3.8 |
Comparative example 2 | 2.6 | 3.6 | 3.8 | 4.0 |
Comparative example 3 | 2.5 | 4.1 | 3.9 | 3.1 |
Comparative example 4 | 3.0 | 5.0 | 3.0 | 3.3 |
As can be seen from Table 1, the chewing tablets of the direct compression type organic calcium vitamin D3 prepared in examples 1-6 of the present invention have faster calcium absorption rate and higher absorption amount, wherein example 6 has the fastest absorption speed and the largest absorption amount, and is the best example of the present invention. The formulations of comparative examples 1 to 4 were compositions of formulations changed based on the formulation of example 6, and it can be seen from table 1 that the absorption rate of calcium and the absorption amount of calcium were decreased.
Test example 2 quality test of directly-compressed organic calcium vitamin D3 chewable tablets
Test samples: calcium-containing vitamin D3 chewable tablets prepared in examples 1-6 and comparative examples 1-4.
The detection method comprises the following steps: the hardness and friability of the direct compression type organic calcium vitamin D3 chewable tablets prepared in examples 1-6 and comparative examples 1-4 are detected by referring to Chinese pharmacopoeia 2010 edition department II.
The test results are shown in table 2.
TABLE 2 quality test of direct compression type organic calcium vitamin D3 chewable tablets
Group of | Hardness of | Degree of friability |
Example 1 | Is moderate | Qualified |
Example 2 | Is moderate | Qualified |
Example 3 | Is moderate | Qualified |
Example 4 | Is moderate | Qualified |
Example 5 | Is moderate | Qualified |
Example 6 | Is moderate | Qualified |
Comparative example 1 | Is harder | Fail to be qualified |
Comparative example 2 | Fail to be qualified | Fail to be qualified |
Comparative example 3 | Is moderate | Qualified |
Comparative example 4 | Is harder | Fail to be qualified |
As can be seen from Table 2, the direct-compression organic calcium vitamin D3 chewable tablet prepared by the invention has moderate hardness, and the friability accords with the regulations of Chinese pharmacopoeia.
Test example 3 vitamin D3 stability test in directly compressed organic calcium vitamin D3 chewable tablets
Test samples: calcium-containing vitamin D3 chewable tablets prepared in examples 1-6 and comparative examples 1-4.
The test method comprises the following steps: irradiating 50 chewable tablets of organic calcium vitamin D3 under 4000 lux daylight for 10 days, sampling at 4 th, 7 th and 10 th days, and measuring the residual rate of vitamin D3 before and after the test by using a high performance liquid chromatograph.
The results of the experiment are shown in table 3.
TABLE 3 vitamin D3 stability test
As can be seen from Table 3, the vitamin D3 residual rate of the direct compression type organic calcium vitamin D3 chewable tablet provided by the invention is more than 90% after being irradiated under 4000 lux daylight for 10 days, and the stability is higher, while the stability effect of D3 in the calcium-containing vitamin D3 chewable tablet prepared in comparative examples 1-4 is poorer, which indicates that the direct compression type organic calcium vitamin D3 chewable tablet provided by the invention has a reasonable formula, and each component has the function of mutually coordinating and enhancing the stability of vitamin D3.
It should be noted that the above-mentioned embodiments are only preferred embodiments of the present invention, and the present invention is not limited thereto, and although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that modifications and equivalents can be made in the technical solutions described in the foregoing embodiments, or some technical features can be replaced. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (6)
1. The direct-compression type organic calcium vitamin D3 chewable tablet is characterized by comprising the following components in parts by weight: 90-130 parts of organic calcium, 25-45 parts of binder, 1-10 parts of anhydrous glucose, 10-30 parts of D-mannitol, 60001-10 parts of polyethylene glycol, 35-25 parts of vitamin D, 0.5-1.5 parts of absorption enhancer, 1-9 parts of sucralose and 0.5-2 parts of magnesium stearate.
2. The direct compression type organic calcium vitamin D3 chewable tablet according to claim 1, is characterized by comprising the following components in parts by weight: 114 parts of organic calcium, 34 parts of binder, 5 parts of anhydrous glucose, 23.38 parts of D-mannitol, 60004 parts of polyethylene glycol, 312 parts of vitamin D, 1 part of absorption enhancer, 5 parts of sucralose and 1.62 parts of magnesium stearate.
3. The direct compression type organic calcium vitamin D3 chewable tablet according to claim 1 or 2, wherein the organic calcium comprises L-calcium lactate and calcium citrate at a weight ratio of 4-6: 5-7.
4. The direct compression type organic calcium vitamin D3 chewable tablet according to claim 3, wherein the organic calcium comprises L-calcium lactate and calcium citrate at a weight ratio of 5: 6.4.
5. The direct compression type organic calcium vitamin D3 chewable tablet of claim 1, wherein the binder is microcrystalline cellulose and the absorption enhancer is polydextrose.
6. The method for preparing the direct compression type organic calcium vitamin D3 chewable tablet according to any one of claims 1 to 5, comprising the following steps:
s1, removing the outer package of organic calcium, binder, anhydrous glucose, D-mannitol, polyethylene glycol, vitamin D3, absorption enhancer, sucralose and magnesium stearate, and irradiating for 30 minutes under an ultraviolet lamp;
s2, sieving the D-mannitol with a 20-mesh sieve, and weighing the components according to the formula;
s3, adding sucralose, vitamin D3 and an absorption promoter into a three-dimensional mixer, mixing at the motor frequency of 25-30Hz for 5 minutes, adding organic calcium, a binder, anhydrous glucose, D mannitol, polyethylene glycol 6000 and magnesium stearate, and continuously mixing for 15 minutes;
s4, tabletting the uniformly mixed materials, bottling and sealing to obtain the finished product.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911001903.0A CN112370429A (en) | 2019-10-21 | 2019-10-21 | Direct-compression type organic calcium vitamin D3 chewable tablet and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911001903.0A CN112370429A (en) | 2019-10-21 | 2019-10-21 | Direct-compression type organic calcium vitamin D3 chewable tablet and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112370429A true CN112370429A (en) | 2021-02-19 |
Family
ID=74585942
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911001903.0A Pending CN112370429A (en) | 2019-10-21 | 2019-10-21 | Direct-compression type organic calcium vitamin D3 chewable tablet and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112370429A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113750062A (en) * | 2021-09-05 | 2021-12-07 | 西安麦德森斯医疗科技有限公司 | Organic calcium vitamin D chewable tablet and preparation method thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0872240A1 (en) * | 1997-04-16 | 1998-10-21 | Laboratoires BESINS ISCOVESCO Société anonyme dite : | Solid preparation from vitamins and calcium, its manufacturing process and use |
US20110130370A1 (en) * | 2009-11-27 | 2011-06-02 | Les Laboratories Servier | Pharmaceutical composition comprising a strontium salt, vitamin D and A cyclodextrin |
GB201311769D0 (en) * | 2013-07-01 | 2013-08-14 | Hmer Thomas B | Product |
WO2015020191A1 (en) * | 2013-08-09 | 2015-02-12 | 日東薬品工業株式会社 | Calcium agent |
CN107823150A (en) * | 2017-10-25 | 2018-03-23 | 北京素维生物科技有限公司 | It is a kind of can rapid dispersion tablet and preparation method thereof |
CN108478595A (en) * | 2018-05-01 | 2018-09-04 | 王康俊 | A kind of pharmaceutical composition containing calcium carbonate, vitamine D3, farnoquinone |
CN108653324A (en) * | 2018-06-26 | 2018-10-16 | 海南金贝康制药有限公司 | One kind of multiple vitamin calcium zinc chewable tablets and its manufacturing method |
-
2019
- 2019-10-21 CN CN201911001903.0A patent/CN112370429A/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0872240A1 (en) * | 1997-04-16 | 1998-10-21 | Laboratoires BESINS ISCOVESCO Société anonyme dite : | Solid preparation from vitamins and calcium, its manufacturing process and use |
US20110130370A1 (en) * | 2009-11-27 | 2011-06-02 | Les Laboratories Servier | Pharmaceutical composition comprising a strontium salt, vitamin D and A cyclodextrin |
GB201311769D0 (en) * | 2013-07-01 | 2013-08-14 | Hmer Thomas B | Product |
WO2015020191A1 (en) * | 2013-08-09 | 2015-02-12 | 日東薬品工業株式会社 | Calcium agent |
CN107823150A (en) * | 2017-10-25 | 2018-03-23 | 北京素维生物科技有限公司 | It is a kind of can rapid dispersion tablet and preparation method thereof |
CN108478595A (en) * | 2018-05-01 | 2018-09-04 | 王康俊 | A kind of pharmaceutical composition containing calcium carbonate, vitamine D3, farnoquinone |
CN108653324A (en) * | 2018-06-26 | 2018-10-16 | 海南金贝康制药有限公司 | One kind of multiple vitamin calcium zinc chewable tablets and its manufacturing method |
Non-Patent Citations (5)
Title |
---|
傅超美 刘文主编: "《中药药剂学实验》", 31 August 2018, 中国医药科技出版社 * |
汪勇主编: "《粮油副产品加工学》", 31 January 2019, 暨南大学出版社 * |
福州军区药物专业组编: "《药物学》", 20 December 1973, 福州军区后勤部卫生部印 * |
秦序锋等: ""小儿碳酸钙维D3咀嚼片处方工艺研究"", 《海峡药学》 * |
陆彬主编: "《药物新剂型与新技术》", 30 April 1998, 人民卫生出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113750062A (en) * | 2021-09-05 | 2021-12-07 | 西安麦德森斯医疗科技有限公司 | Organic calcium vitamin D chewable tablet and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112189711A (en) | Milk powder for assisting in reducing hypertension, hyperglycemia and hyperlipidemia of middle-aged and old people | |
CN101766635B (en) | Composite for disintoxicating and sobering | |
CN101049150A (en) | Edible nourishment health care potassium salt with extensive use | |
AU777261B2 (en) | Folic acid supplement | |
CN104922115A (en) | Anti-fatigue agent comprising amino acid composition | |
CN101268835A (en) | Nutrition high calcium medicinal granule for children and preparing technique | |
CN101720956B (en) | Banana drink and method for preparing same | |
CN107929313A (en) | Natural type oyster shell calcium preparation for preventing and treating acalcicosis and preparation method thereof | |
CN105918742A (en) | Beverage capable of promoting sleep, expelling toxins, and nourishing skin | |
CN101279089B (en) | Donkey-hide gelatin calcium composition and preparing process thereof | |
CN101176734A (en) | Nutrients replenisher for replenishing folic acid and vitamin B12 and preparation method thereof | |
KR101896024B1 (en) | Functional food compositions comprising extracts of Garcinia Cambogia as active ingredients and method for preparing the same | |
CN1679628A (en) | Yak myeloid calcium tablets | |
CN112370429A (en) | Direct-compression type organic calcium vitamin D3 chewable tablet and preparation method thereof | |
EP2030629B1 (en) | Alpha-s-casein as lipid-metabolism-improving agent | |
CN103735556A (en) | Multivitamin mineral composite effervescent tablet and preparation method thereof | |
KR20140017977A (en) | Vita hybrid tablet for senior and manufacturing method thereof | |
CN107912591A (en) | A kind of blueberry essence piece pressed candy | |
CN101253984A (en) | Royal jelly ginkgo leaf nutrition health products and method of preparing the same | |
JP3433917B2 (en) | Nutritional composition for enhancing body protein accumulation efficiency | |
CN107373273B (en) | Adult type multivitamin mineral effervescent tablet and preparation method thereof | |
CN114680339A (en) | Nutritional supplement for improving muscle attenuation and delaying senescence and application thereof | |
CN104126806A (en) | Vitamin B12 sublingual tablet and preparation method thereof | |
CN101129406A (en) | Formula of compound colla carapaeis corii asini series products and method for producing the same | |
CN102342400A (en) | High-calcium xylitol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210219 |
|
RJ01 | Rejection of invention patent application after publication |